A Phase 4 interventional study of Aripiprazole and Placebo in Tourette's Disorder (TD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 42 sites in 3 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-03-09.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.
Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 4, and was the 10th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2018.
This study's enrollment of 36 is close to the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 97 across the 10 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 9 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing aripiprazole in Tourette Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).
This study will evaluate the long-term efficacy of oral aripiprazole in the treatment of pediatric participants with Tourette's Disorder (TD). The trial consists of 3 distinct phases: a pretreatment phase, open-label stabilization phase, and a double-blind randomized withdrawal phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.
Drug: Aripiprazole
Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for \<50 kg participants,and 10 mg or 20 mg for \>50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
Drug: Aripiprazole
Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for \<50 kg participants, and 5 mg or 10 mg for \>50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
Drug: Aripiprazole
Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.
Drug: Placebo
Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
Also known as: OPC-14597
Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase
Relapse was defined as a loss of ≥ 50% of the improvement experienced during the open-label stabilization phase (i.e., improvement at the last assessment of Yale Global Tic Severity Scale (YGTSS) before randomization) on the Yale Global Tic Severity Scale Total Tic Score (YGTSS TTS). YGTSS provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic symptoms.
Time frame: From Randomization up to 12 weeks in Double-blind Randomized Withdrawal Phase
Participants took part in the study at 13 investigative sites in Canada, the United States and Hungary from Oct 13, 2018 to Jun 30, 2020.
| Milestone | Open Label Stabilization Phase: Aripiprazole | Double Blind Phase: Aripiprazole Full Dose | Double Blind Phase: Aripiprazole Half Dose | Double Blind Phase: Placebo |
|---|---|---|---|---|
| Started | 36 | 0 | 0 | 0 |
| Completed | 25 | 0 | 0 | 0 |
| Not completed | 11 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 0 | 0 | 0 |
| Milestone | Open Label Stabilization Phase: Aripiprazole | Double Blind Phase: Aripiprazole Full Dose | Double Blind Phase: Aripiprazole Half Dose | Double Blind Phase: Placebo |
|---|---|---|---|---|
| Started | 0 | 9 | 8 | 8 |
| Completed | 0 | 7 | 7 | 0 |
| Not completed | 0 | 2 | 1 | 8 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Disease relapse | 0 | 0 | 0 | 6 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 1 | 1 |
Relapse was defined as a loss of ≥ 50% of the improvement experienced during the open-label stabilization phase (i.e., improvement at the last assessment of Yale Global Tic Severity Scale (YGTSS) before randomization) on the Yale Global Tic Severity Scale Total Tic Score (YGTSS TTS). YGTSS provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic symptoms.
| percentage of participants | Double Blind Phase: Aripiprazole Full Dose | Double Blind Phase: Aripiprazole Half Dose | Double Blind Phase: Placebo |
|---|---|---|---|
| Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase | 0.0 | 0.0 | 75.0 |
Collected over From first dose up to 30 days after last dose of study drug (Up to approximately 36 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Stabilization Phase: Aripiprazole | 0/36 (0%) | 0/36 (0%) | 17/36 (47.2%) |
| Double Blind Phase: Aripiprazole Full Dose | 0/9 (0%) | 1/9 (11.1%) | 3/9 (33.3%) |
| Double Blind Phase: Aripiprazole Half Dose | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Double Blind Phase: Placebo | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | Open Label Stabilization Phase: Aripiprazole | Double Blind Phase: Aripiprazole Full Dose | Double Blind Phase: Aripiprazole Half Dose | Double Blind Phase: Placebo |
|---|---|---|---|---|
| Suicidal IdeationPsychiatric disorders | 0/36 | 1/9 | 0/8 | 0/8 |
| Event | Open Label Stabilization Phase: Aripiprazole | Double Blind Phase: Aripiprazole Full Dose | Double Blind Phase: Aripiprazole Half Dose | Double Blind Phase: Placebo |
|---|---|---|---|---|
| FatigueGeneral disorders | 7/36 | 0/9 | 0/8 | 0/8 |
| SomnolenceNervous system disorders | 5/36 | 0/9 | 1/8 | 0/8 |
| Pharyngitis streptococcalInfections and infestations | 0/36 | 0/9 | 1/8 | 0/8 |
| Urinary tract infectionInfections and infestations | 0/36 | 0/9 | 1/8 | 0/8 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/36 | 0/9 | 1/8 | 0/8 |
| AggressionPsychiatric disorders | 0/36 | 0/9 | 0/8 | 1/8 |
| IrritabilityPsychiatric disorders | 1/36 | 0/9 | 0/8 | 1/8 |
| RestlessnessPsychiatric disorders | 1/36 | 0/9 | 0/8 | 1/8 |
| TachycardiaCardiac disorders | 1/36 | 1/9 | 0/8 | 0/8 |
| Upper respiratory tract infectionInfections and infestations | 1/36 | 1/9 | 0/8 | 0/8 |
The Enrolled Sample included all participants who entered the open-label stabilization phase.
| Age, Continuous(years) | Open Label Stabilization Phase: Aripiprazole |
|---|---|
| Mean | 10.9 ± 3.0 |
| Sex: Female, Male(Participants) | Open Label Stabilization Phase: Aripiprazole |
|---|---|
| Female | 6 |
| Male | 30 |
| Ethnicity (NIH/OMB)(Participants) | Open Label Stabilization Phase: Aripiprazole |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 29 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Open Label Stabilization Phase: Aripiprazole |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 32 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | Open Label Stabilization Phase: Aripiprazole |
|---|---|
| Canada | 9 |
| Hungary | 4 |
| United States | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Oct 2018 to primary completion in Jun 2020, 20 months.
Results were first posted in Jan 2021, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →